{"id":"levalbuterol-r-albuterol","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Tremor"},{"rate":"5-15","effect":"Nervousness"},{"rate":"5-10","effect":"Headache"},{"rate":"2-5","effect":"Palpitations"},{"rate":"2-5","effect":"Tachycardia"},{"rate":"2-5","effect":"Muscle cramps"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Levalbuterol is the pharmacologically active isomer of the racemic mixture albuterol. By selectively activating beta-2 adrenergic receptors, it triggers smooth muscle relaxation in the airways, leading to rapid bronchodilation. The R-enantiomer is approximately 50-fold more potent at the beta-2 receptor than the S-enantiomer, potentially allowing for lower doses and reduced systemic side effects compared to racemic albuterol.","oneSentence":"Levalbuterol is the active R-enantiomer of albuterol that selectively binds to and activates beta-2 adrenergic receptors on airway smooth muscle, causing bronchodilation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:34:01.701Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute bronchospasm in asthma and COPD"},{"name":"Prevention of exercise-induced bronchospasm"}]},"trialDetails":[{"nctId":"NCT06036823","phase":"PHASE4","title":"5 Versus 10 Units of Insulin in Hyperkalemia Management","status":"COMPLETED","sponsor":"Oman Medical Speciality Board","startDate":"2023-10-01","conditions":"Hyperkalemia, Potassium Imbalance, Electrolyte Imbalance","enrollment":384},{"nctId":"NCT07052942","phase":"PHASE4","title":"Individualizing Treatment for Asthma in Primary Care (Full Study)","status":"RECRUITING","sponsor":"DARTNet Institute","startDate":"2025-08-01","conditions":"Asthma, Asthma Attack, Asthma Exacerbations","enrollment":3200},{"nctId":"NCT06618105","phase":"PHASE3","title":"Bronchoprovocation Study to Demonstrate the Pharmacodynamic Bioequivalence of Albuterol Sulfate HFA Inhalation Aerosol (E.Q. 90 mcg of Albuterol Base/Inh) of Macleods Pharmaceuticals Ltd","status":"NOT_YET_RECRUITING","sponsor":"Macleods Pharmaceuticals Ltd","startDate":"2024-10-15","conditions":"Mild Asthma","enrollment":144},{"nctId":"NCT05664061","phase":"PHASE3","title":"Bioequivalence With Clinical Endpoint Study of Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma","status":"UNKNOWN","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2023-01-30","conditions":"Asthma","enrollment":451},{"nctId":"NCT04790838","phase":"","title":"Pooled Analysis FP_SX_250_50","status":"COMPLETED","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2019-06-02","conditions":"Asthma","enrollment":82},{"nctId":"NCT03676413","phase":"PHASE3","title":"A Clinical Trial for Examining the Therapeutic Equivalence Between Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma","status":"COMPLETED","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2018-10-02","conditions":"Asthma","enrollment":451},{"nctId":"NCT03524066","phase":"NA","title":"Lung Pharmacokinetics (PK) in Epithelial Lining Fluid (ELF)","status":"COMPLETED","sponsor":"Fraunhofer-Institute of Toxicology and Experimental Medicine","startDate":"2018-04-10","conditions":"Healthy","enrollment":21},{"nctId":"NCT02914652","phase":"PHASE4","title":"The Cardiopulmonary Effect of Inhaled Beta-2-agonists on Adult Patients Born With Ventricular Septum Defects.","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2016-10-15","conditions":"Ventricular Septal Defect","enrollment":96},{"nctId":"NCT01189396","phase":"PHASE2","title":"Escalating and Cumulative-Dose Study of Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of A006","status":"COMPLETED","sponsor":"Amphastar Pharmaceuticals, Inc.","startDate":"2010-07","conditions":"Asthma, Bronchospasm, Chronic Obstructive Pulmonary Disease (COPD)","enrollment":27},{"nctId":"NCT00635505","phase":"PHASE3","title":"Controlled, 12-Week Study of Albuterol HFA Versus the Active Control, Proventil(R)-HFA in Asthmatic Patients","status":"TERMINATED","sponsor":"Amphastar Pharmaceuticals, Inc.","startDate":"2007-09","conditions":"Asthma","enrollment":300},{"nctId":"NCT00634517","phase":"PHASE3","title":"4-Week Study of Efficacy, Safety and PK of Albuterol-HFA Versus Proventil-HFA in Pediatric Asthma","status":"TERMINATED","sponsor":"Amphastar Pharmaceuticals, Inc.","startDate":"2008-03","conditions":"Asthma","enrollment":48},{"nctId":"NCT00634829","phase":"PHASE3","title":"Single-Dose Cross-Over Study of the Effects of Albuterol-HFA in Exercise Induced Bronchoconstriction","status":"TERMINATED","sponsor":"Amphastar Pharmaceuticals, Inc.","startDate":"2008-02","conditions":"Asthma, Bronchospasm","enrollment":24},{"nctId":"NCT00124176","phase":"PHASE4","title":"Continuous Levalbuterol for Treatment of Status Asthmaticus in Children","status":"COMPLETED","sponsor":"Children's Hospital of Philadelphia","startDate":"2004-04","conditions":"Asthma","enrollment":81},{"nctId":"NCT00685841","phase":"PHASE3","title":"A Pivotal Study of the Safety and Effectiveness of Arformoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2002-02","conditions":"COPD","enrollment":717},{"nctId":"NCT00064402","phase":"PHASE3","title":"Determine the Safety and Efficacy of (R,R)-Formoterol in the Treatment of Subjects With COPD","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2002-04","conditions":"Chronic Obstructive Pulmonary Disease, Chronic Bronchitis, Emphysema","enrollment":741},{"nctId":"NCT00685126","phase":"PHASE3","title":"Study of Levalbuterol and Racemic Albuterol in Pediatric Subjects With Reactive Airways Disease (RAD)","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2001-02","conditions":"Reactive Airways Disease (RAD)","enrollment":117},{"nctId":"NCT00064415","phase":"PHASE3","title":"To Evaluate the Long-term Safety of (R,R)-Formoterol in Subjects With COPD","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2002-06","conditions":"Chronic Obstructive Pulmonary Disease, Chronic Bronchitis, Emphysema","enrollment":799},{"nctId":"NCT00320034","phase":"PHASE2","title":"Evaluation of the Effect of Levalbuterol on Allergen Induced Airway Inflammation In Subjects With Atopic Asthma","status":"COMPLETED","sponsor":"Hamilton Health Sciences Corporation","startDate":"2006-04","conditions":"Asthma","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":26,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Xopenex"],"phase":"marketed","status":"active","brandName":"Levalbuterol (R albuterol)","genericName":"Levalbuterol (R albuterol)","companyName":"Children's Hospital of Philadelphia","companyId":"children-s-hospital-of-philadelphia","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Levalbuterol is the active R-enantiomer of albuterol that selectively binds to and activates beta-2 adrenergic receptors on airway smooth muscle, causing bronchodilation. Used for Acute bronchospasm in asthma and COPD, Prevention of exercise-induced bronchospasm.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}